ESMO 2019 Congress | OncologyPRO

Abstract 1595

Background

Recent evidence supported that netrin-1 involves in colorectal carcinogenesis. This study was to evaluate the performance of serum netrin-1 for detection of colorectal cancer (CRC) in both a clinical set and a screening set.

Methods

A total of 115 consecutive patients with CRC and matched healthy controls were included in Clinical Set. Fifty subjects with CRC, 50 subjects with advanced adenoma (AA), and 150 matched control participants free of neoplasia were included in Screening Set. Circulating levels of netrin-1 were evaluated with commercial ELISA kits.

Results

In Clinical set, subjects with CRC presented higher levels of serum netrin-1 (513.9 ± 22.6 pg/mL) than controls (347.8 ± 20.3 pg/mL, p < 0.0001). Similar in Screening set, serum levels of netrin-1 was higher in CRC (644.5 ± 37.0 pg/mL), in comparison with controls (407.7 ± 14.8 pg/mL, p < 0.0001) and AA (416.5 ± 18.5 pg/mL, p < 0.0001). However, there was no difference between controls and AA (p = 0.752). Compared with the low netrin-1 group, the high group presented increased risk of CRC (Clinical set: OR = 4.300 [95% CI 2.473 – 7.477], p < 0.001); Screening set: OR = 7.731 [95% CI 3.618 – 16.519], p < 0.001). ROC curve of netrin-1 was developed to detect CRC (Clinical set: AUC 0.703 [95% CI 0.636 – 0.770]; Screening set: AUC 0.759 [95% CI 0.680 – 0.837]).Table: 147P

Study population characteristics

	Clinical set	Screening set
	Controls	CRC	Controls	AA	CRC
Number	115	115	150	50	50
Netrin-1 levels (pg/ml)	347.8 ± 20.3*	513.9 ± 22.6*	407.7 ± 14.8^#	416.5 ± 18.5^	644.5 ± 37.0^#^
Age (years)	53.8 ± 8.7	55.9 ± 9.1	54.2 ± 9.2	51.9 ± 10.0	55.8 ± 9.6
Sex
Male	92	92	111	37	37
Female	23	23	39	13	13
BMI (kg/m²)	22.8 ± 3.0	24.6 ± 3.9	22.4 ± 2.9	23.1 ± 3.1	23.7 ± 3.1
WHR	0.89 ± 0.08	0.92 ± 0.06	0.88 ± 0.08	0.94 ± 0.09	0.99 ± 0.07
TNM stage
I		16			10
II		43			22
III		42			13
IV		14			5
Location
Colon		83			34
Rectum		32			16

Data are mean ± SD for continuous variables.

p < 0.001; ^#p < 0.001; ^∧p < 0.001. AA, advanced adenomas; BMI, body mass index; WHR, waist-to-hip circumference ratio.

Conclusions

It suggests netrin-1 as a potential biomarker in the screening and detection of CRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The First Affiliated Hospital of Soochow University.

Funding

Jiangsu Provincial Key Research and Development Plan (No. BE2018659) and Provincial Key Laboratory Program of Higher Education (No. KJS1867).

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

30 Sep 2019